Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 InnovivaTrillium TherapeuticsRepare TherapeuticsOmerosAnnexon
SymbolNASDAQ:INVANASDAQ:TRILNASDAQ:RPTXNASDAQ:OMERNASDAQ:ANNX
Price Information
Current Price$11.90$9.98$33.68$18.37$23.42
52 Week RangeSellBuyBuyBuyBuy
MarketRank™
Overall Score1.41.71.61.41.9
Analysis Score0.53.42.53.33.5
Community Score2.12.93.82.93.5
Dividend Score0.00.00.00.00.0
Ownership Score3.31.70.80.81.7
Earnings & Valuation Score1.30.60.60.00.6
Analyst Ratings
Consensus RecommendationSellBuyBuyBuyBuy
Consensus Price Target$10.00$21.83$39.40$23.40$34.33
% Upside from Price Target-15.97% downside118.77% upside16.98% upside27.38% upside46.60% upside
Trade Information
Market Cap$1.21 billion$1.03 billion$1.25 billion$1.14 billion$893.66 million
Beta0.642.27N/A1.65N/A
Average Volume542,6711,310,308151,635741,821162,907
Sales & Book Value
Annual Revenue$261.02 million$120,000.00N/A$111.81 millionN/A
Price / Sales4.628,567.91N/A10.18N/A
Cashflow$1.69 per shareN/AN/AN/AN/A
Price / Cash7.03N/AN/AN/AN/A
Book Value$3.38 per share($0.86) per shareN/A($2.19) per shareN/A
Price / Book3.52-11.60N/A-8.39N/A
Profitability
Net Income$157.29 million$-41,620,000.00N/A$-84,490,000.00$-37,180,000.00
EPS$1.43($1.38)N/A($0.96)N/A
Trailing P/E Ratio6.07N/A0.00N/A0.00
Forward P/E Ratio6.92N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins67.16%N/AN/A-134.59%N/A
Return on Equity (ROE)53.99%-70.00%N/AN/A-566.22%
Return on Assets (ROA)28.92%-28.84%N/A-59.49%-32.99%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.72%N/AN/AN/AN/A
Current Ratio146.75%22.44%35.44%4.11%41.56%
Quick Ratio146.75%22.44%35.44%4.07%41.56%
Ownership Information
Institutional Ownership Percentage71.48%67.46%64.81%56.63%91.20%
Insider Ownership Percentage0.32%N/AN/A11.30%N/A
Miscellaneous
Employees5N/A10227748
Shares Outstanding101.39 million103.02 million36.98 million61.93 million38.16 million
Next Earnings Date5/5/2021 (Estimated)5/21/2021 (Estimated)6/3/2021 (Estimated)5/10/2021 (Estimated)6/24/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableNot Optionable
SourceHeadline
Annexon (NASDAQ:ANNX) Trading 4% Higher Annexon (NASDAQ:ANNX) Trading 4% Higher
americanbankingnews.com - April 15 at 12:00 PM
Annexon, Inc. (NASDAQ:ANNX) Short Interest UpdateAnnexon, Inc. (NASDAQ:ANNX) Short Interest Update
americanbankingnews.com - April 15 at 1:48 AM
Annexon (NASDAQ:ANNX) Shares Gap Up to $23.25Annexon (NASDAQ:ANNX) Shares Gap Up to $23.25
americanbankingnews.com - April 13 at 1:42 PM
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by AnalystsAnnexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Buy" by Analysts
americanbankingnews.com - April 11 at 4:28 AM
Annexon (NASDAQ:ANNX) Trading Down 4.6%Annexon (NASDAQ:ANNX) Trading Down 4.6%
americanbankingnews.com - April 7 at 12:32 PM
Heres Why Were Not Too Worried About Annexons (NASDAQ:ANNX) Cash Burn SituationHere's Why We're Not Too Worried About Annexon's (NASDAQ:ANNX) Cash Burn Situation
nasdaq.com - April 7 at 11:31 AM
Annexon (NASDAQ:ANNX) Shares Gap Down to $27.33Annexon (NASDAQ:ANNX) Shares Gap Down to $27.33
americanbankingnews.com - April 6 at 11:00 AM
Annexon (NASDAQ:ANNX) Trading 8.9% Higher Annexon (NASDAQ:ANNX) Trading 8.9% Higher
americanbankingnews.com - March 31 at 1:46 PM
Annexon (NASDAQ:ANNX) Stock Price Down 9.4% on Insider SellingAnnexon (NASDAQ:ANNX) Stock Price Down 9.4% on Insider Selling
americanbankingnews.com - March 29 at 12:28 PM
Annexon (NASDAQ:ANNX) Shares Gap Down  on Disappointing EarningsAnnexon (NASDAQ:ANNX) Shares Gap Down on Disappointing Earnings
americanbankingnews.com - March 26 at 12:10 PM
Annexon (NASDAQ:ANNX) Posts Quarterly  Earnings Results, Misses Expectations By $0.17 EPSAnnexon (NASDAQ:ANNX) Posts Quarterly Earnings Results, Misses Expectations By $0.17 EPS
americanbankingnews.com - March 25 at 2:18 PM
Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent ...Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent ...
apnews.com - March 25 at 9:51 AM
Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business HighlightsAnnexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights
finance.yahoo.com - March 25 at 9:51 AM
Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder TherapyAnnexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy
finance.yahoo.com - March 1 at 6:26 PM
Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial ...Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial ...
apnews.com - March 1 at 8:25 AM
Annexon Welcomes William H. Carson, M.D. to the Board of DirectorsAnnexon Welcomes William H. Carson, M.D. to the Board of Directors
finance.yahoo.com - February 8 at 8:47 AM
Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its ...Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its ...
apnews.com - January 13 at 8:14 AM
Annexon to Present at the J.P. Morgan 39th Annual Healthcare ConferenceAnnexon to Present at the J.P. Morgan 39th Annual Healthcare Conference
finance.yahoo.com - January 5 at 12:05 PM
Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré SyndromeAnnexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome
finance.yahoo.com - December 21 at 7:50 AM
Is ANNX A Good Stock To Buy Now?Is ANNX A Good Stock To Buy Now?
finance.yahoo.com - December 11 at 2:45 PM
Annexon Biosciences EPS misses by $0.43Annexon Biosciences EPS misses by $0.43
seekingalpha.com - November 16 at 6:44 PM
Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with ...Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with ...
apnews.com - November 13 at 10:06 AM
Annexon launches Phase 2 study of monoclonal antibody in Huntington’sAnnexon launches Phase 2 study of monoclonal antibody in Huntington’s
seekingalpha.com - November 12 at 6:41 PM
Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical ProgramAnnexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program
finance.yahoo.com - November 12 at 6:41 PM
Were Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash WiselyWe're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
sports.yahoo.com - October 24 at 1:03 PM
DateCompanyBrokerageAction
11/11/2020InnovivaMorgan StanleyBoost Price Target
6/25/2018InnovivaStifel NicolausReiterated Rating
4/19/2018InnovivaBerenberg BankInitiated Coverage
4/14/2021Trillium TherapeuticsBenchmarkInitiated Coverage
3/22/2021Trillium TherapeuticsHC WainwrightReiterated Rating
3/19/2021Trillium TherapeuticsJonestradingReiterated Rating
12/8/2020Trillium TherapeuticsBloom BurtonDowngrade
11/18/2020Trillium TherapeuticsCraig HallumBoost Price Target
10/12/2020Trillium TherapeuticsEvercore ISIInitiated Coverage
9/9/2020Trillium TherapeuticsJMP SecuritiesBoost Price Target
1/7/2020Trillium TherapeuticsCowenReiterated Rating
12/29/2020Repare TherapeuticsNorthland SecuritiesReiterated Rating
7/14/2020Repare TherapeuticsThe Goldman Sachs GroupInitiated Coverage
7/14/2020Repare TherapeuticsPiper SandlerInitiated Coverage
2/1/2021OmerosUBS GroupInitiated Coverage
12/4/2020OmerosMaxim GroupBoost Price Target
10/20/2020OmerosBank of AmericaInitiated Coverage
9/1/2020OmerosWedbushLower Price Target
5/12/2020OmerosNeedham & Company LLCReiterated Rating
9/1/2020AnnexonRobert W. BairdInitiated Coverage
8/18/2020AnnexonJPMorgan Chase & Co.Initiated Coverage
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.